Logo image of ANIX

ANIXA BIOSCIENCES INC (ANIX) Stock Fundamental Analysis

USA - NASDAQ:ANIX - US03528H1095 - Common Stock

4.2 USD
+0.09 (+2.19%)
Last: 11/17/2025, 8:00:01 PM
4.2925 USD
+0.09 (+2.2%)
After Hours: 11/17/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, ANIX scores 3 out of 10 in our fundamental rating. ANIX was compared to 533 industry peers in the Biotechnology industry. ANIX has a great financial health rating, but its profitability evaluates not so good. ANIX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ANIX had negative earnings in the past year.
ANIX had a negative operating cash flow in the past year.
In the past 5 years ANIX always reported negative net income.
ANIX had a negative operating cash flow in each of the past 5 years.
ANIX Yearly Net Income VS EBIT VS OCF VS FCFANIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

1.2 Ratios

ANIX's Return On Assets of -62.97% is in line compared to the rest of the industry. ANIX outperforms 40.90% of its industry peers.
With a Return On Equity value of -66.98%, ANIX perfoms like the industry average, outperforming 58.35% of the companies in the same industry.
Industry RankSector Rank
ROA -62.97%
ROE -66.98%
ROIC N/A
ROA(3y)-47.1%
ROA(5y)-56.61%
ROE(3y)-49.97%
ROE(5y)-60.17%
ROIC(3y)N/A
ROIC(5y)N/A
ANIX Yearly ROA, ROE, ROICANIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANIX Yearly Profit, Operating, Gross MarginsANIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

8

2. Health

2.1 Basic Checks

ANIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ANIX has more shares outstanding
ANIX has more shares outstanding than it did 5 years ago.
ANIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANIX Yearly Shares OutstandingANIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ANIX Yearly Total Debt VS Total AssetsANIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

An Altman-Z score of 57.62 indicates that ANIX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 57.62, ANIX belongs to the best of the industry, outperforming 97.19% of the companies in the same industry.
ANIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 57.62
ROIC/WACCN/A
WACC8.78%
ANIX Yearly LT Debt VS Equity VS FCFANIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

ANIX has a Current Ratio of 8.45. This indicates that ANIX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ANIX (8.45) is better than 75.42% of its industry peers.
ANIX has a Quick Ratio of 8.45. This indicates that ANIX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ANIX (8.45) is better than 75.42% of its industry peers.
Industry RankSector Rank
Current Ratio 8.45
Quick Ratio 8.45
ANIX Yearly Current Assets VS Current LiabilitesANIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

1

3. Growth

3.1 Past

ANIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.26%, which is quite good.
ANIX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)10.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 2.12% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.46%
EPS Next 2Y6.22%
EPS Next 3Y6.72%
EPS Next 5Y2.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANIX Yearly Revenue VS EstimatesANIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2021 2023 2029 2030 2031 2032 100M 200M 300M 400M
ANIX Yearly EPS VS EstimatesANIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5

0

4. Valuation

4.1 Price/Earnings Ratio

ANIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANIX Price Earnings VS Forward Price EarningsANIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANIX Per share dataANIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.22%
EPS Next 3Y6.72%

0

5. Dividend

5.1 Amount

ANIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ANIXA BIOSCIENCES INC

NASDAQ:ANIX (11/17/2025, 8:00:01 PM)

After market: 4.2925 +0.09 (+2.2%)

4.2

+0.09 (+2.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-10 2025-09-10/amc
Earnings (Next)01-08 2026-01-08/amc
Inst Owners14.64%
Inst Owner Change1.83%
Ins Owners2.42%
Ins Owner Change4.36%
Market Cap138.26M
Revenue(TTM)N/A
Net Income(TTM)-11.12M
Analysts82
Price Target9.18 (118.57%)
Short Float %1.63%
Short Ratio2.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.76%
Min EPS beat(2)11.76%
Max EPS beat(2)23.75%
EPS beat(4)3
Avg EPS beat(4)8.42%
Min EPS beat(4)-3.81%
Max EPS beat(4)23.75%
EPS beat(8)5
Avg EPS beat(8)4.3%
EPS beat(12)8
Avg EPS beat(12)10.96%
EPS beat(16)11
Avg EPS beat(16)8.35%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-4.16%
EPS NQ rev (3m)20.64%
EPS NY rev (1m)4.11%
EPS NY rev (3m)11.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.33
P/tB 8.33
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.97%
ROE -66.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.1%
ROA(5y)-56.61%
ROE(3y)-49.97%
ROE(5y)-60.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.45
Quick Ratio 8.45
Altman-Z 57.62
F-Score4
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y8.46%
EPS Next 2Y6.22%
EPS Next 3Y6.72%
EPS Next 5Y2.12%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.41%
OCF growth 3YN/A
OCF growth 5YN/A

ANIXA BIOSCIENCES INC / ANIX FAQ

Can you provide the ChartMill fundamental rating for ANIXA BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to ANIX.


What is the valuation status for ANIX stock?

ChartMill assigns a valuation rating of 0 / 10 to ANIXA BIOSCIENCES INC (ANIX). This can be considered as Overvalued.


Can you provide the profitability details for ANIXA BIOSCIENCES INC?

ANIXA BIOSCIENCES INC (ANIX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ANIXA BIOSCIENCES INC?

The Earnings per Share (EPS) of ANIXA BIOSCIENCES INC (ANIX) is expected to grow by 8.46% in the next year.